Insider Selling: Insulet Co. (NASDAQ:PODD) CAO Sells 915 Shares of Stock

Insulet Co. (NASDAQ:PODD) CAO Lauren Budden sold 915 shares of Insulet stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the sale, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at $1,580,129.46. This trade represents a 13.76 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Insulet Stock Performance

NASDAQ:PODD opened at $269.34 on Friday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The stock has a market capitalization of $18.89 billion, a PE ratio of 46.12, a P/E/G ratio of 4.18 and a beta of 1.21. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $279.77. The company has a fifty day moving average of $251.37 and a two-hundred day moving average of $220.02.

Wall Street Analyst Weigh In

Several analysts have commented on PODD shares. Canaccord Genuity Group lifted their price objective on shares of Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a research note on Monday, December 9th. BTIG Research boosted their target price on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Raymond James increased their price target on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research report on Monday, October 14th. Morgan Stanley boosted their price objective on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a report on Monday, November 11th. Finally, Sanford C. Bernstein assumed coverage on Insulet in a report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $267.44.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. B. Riley Wealth Advisors Inc. acquired a new stake in Insulet in the 3rd quarter worth about $202,000. Synovus Financial Corp boosted its stake in shares of Insulet by 36.1% in the third quarter. Synovus Financial Corp now owns 2,929 shares of the medical instruments supplier’s stock worth $682,000 after acquiring an additional 777 shares during the last quarter. Tidal Investments LLC increased its position in shares of Insulet by 5.2% during the third quarter. Tidal Investments LLC now owns 9,365 shares of the medical instruments supplier’s stock worth $2,180,000 after purchasing an additional 466 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Insulet during the third quarter worth approximately $114,000. Finally, Virtu Financial LLC acquired a new position in Insulet in the 3rd quarter valued at $616,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.